Welcome to our dedicated page for OmniAb SEC filings (Ticker: OABI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OmniAb, Inc. (NASDAQ: OABI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing investors with direct access to its official public record. OmniAb is a technology company that licenses discovery research platforms for antibody and peptide therapeutics, and its filings offer detail on how this business is structured and financed.
OmniAb’s current reports on Form 8-K include announcements of quarterly and year-to-date financial results, where the company breaks out revenue from license and milestone agreements, services, xPloration® instrument sales and related consumables, and royalties. These filings also discuss research and development and general and administrative expenses, other operating income, and net loss figures, giving context to the economics of its technology licensing and discovery services model.
Other 8-K filings describe material events such as securities purchase agreements for private placements of common stock. In these documents, OmniAb outlines the number of shares sold, purchase prices, intended use of proceeds for working capital and general corporate purposes, and related registration rights. Filings also confirm that OmniAb’s common stock is listed on The Nasdaq Global Market under the symbol OABI, with warrants listed on The Nasdaq Capital Market under OABIW, and that the company qualifies as an emerging growth company.
Shareholder-focused filings, including reports on annual meetings, provide voting results for director elections and ratification of the independent registered public accounting firm. Together, these SEC documents help investors analyze governance, capital structure, financing transactions, and the financial performance of OmniAb’s antibody discovery technology business. Stock Titan enhances this information with AI-powered summaries that explain key points from forms such as 10-K, 10-Q, 8-K, and ownership reports, helping readers quickly understand the implications of each filing.
OmniAb, Inc. director John L. Higgins reported the vesting of 13,172 restricted stock units (RSUs) and the corresponding acquisition of 13,172 shares of common stock on January 30, 2026.
The RSUs vest in three substantially equal annual installments beginning January 30, 2024, conditioned on his continued service. After this transaction, he beneficially owns 2,942,320 shares of common stock and 20,000 RSUs directly.
OmniAb, Inc. reports that its Board of Directors approved and adopted amended and restated bylaws effective January 30, 2026. The updated bylaws address the SEC’s universal proxy rules by clarifying that no one may solicit proxies for director nominees other than the Board’s nominees unless they comply with Rule 14a-19, including its notice and solicitation requirements.
The bylaws also modernize and enhance procedures for stockholder director nominations and other business at stockholder meetings, requiring additional background information and disclosures about proposing stockholders, proposed nominees, related persons, and their ownership of OmniAb securities. The filing notes further technical, modernizing and clarifying changes, with full text provided in attached exhibits.
OmniAb, Inc.'s Chief Legal Officer acquired 15,621 shares of common stock on December 7, 2025 through the vesting of restricted stock units. On December 8, 2025, 8,044 shares were sold at a weighted average price of $1.96 per share to cover tax withholding obligations in connection with that vesting under a required sell-to-cover arrangement that is not a discretionary trade.
After these transactions, the officer directly owns 377,071 shares of OmniAb common stock and holds 96,876 restricted stock units, each representing a contingent right to receive one share.
OmniAb (OABI) reported insider buying by director John L. Higgins. He purchased common stock in two open‑market transactions. On November 6, 2025, he bought 36,223 shares at a weighted average price of $1.41, with trades ranging from $1.38 to $1.45, bringing his beneficial ownership to 2,888,110 shares afterward.
On November 7, 2025, he bought 41,038 shares at a weighted average price of $1.38, with trades ranging from $1.33 to $1.39, increasing his beneficial ownership to 2,929,148 shares after the transaction.
OmniAb, Inc. reported Q3 2025 results showing lower revenue and continued investment in its platform. Total revenue was $2.239 million (vs. $4.172 million a year ago), and net loss was $16.525 million, or $0.14 per share. For the nine months, revenue was $10.290 million and net loss was $50.600 million.
On the balance sheet, cash and cash equivalents were $28.537 million and short‑term investments were $30.963 million as of September 30, 2025. Operating cash used was $30.781 million for the nine months. Shares outstanding were 143,955,400 as of October 28, 2025.
To support operations, OmniAb completed an August 2025 private placement of 21,254,106 shares at $1.40 (or $1.85 for certain insiders) for approximately $30.0 million in gross proceeds; the resale registration became effective on September 19, 2025. The company also recorded a $3.0 million gain from the sale of an ion channel asset in May 2025.
OmniAb, Inc. reported that it issued a press release announcing financial results for the three and nine months ended September 30, 2025. The press release was furnished as Exhibit 99.1 and is not deemed “filed” under the Exchange Act.
The company’s common stock trades as OABI on the Nasdaq Global Market, and its warrants trade as OABIW on the Nasdaq Capital Market.
OmniAb (OABI) disclosed that a director reported the vesting and settlement of 17,769 restricted stock units into common stock on November 1, 2025 (transaction code M).
Following the transaction, the director beneficially owns 93,308 shares directly and holds 20,000 RSUs. The RSU award vests in three substantially equal annual installments beginning November 1, 2023, subject to continued service. The filing was made by one reporting person with direct ownership.
OmniAb (OABI): Form 4 insider transaction
Director Steven Love reported the vesting and settlement of 13,333 Restricted Stock Units into common stock on 11/01/2025 (Code M). Following the transaction, he beneficially owns 71,666 shares directly. Remaining RSUs beneficially owned total 33,334.
Per the footnote, these RSUs vest in three substantially equal annual installments beginning November 1, 2024, subject to continued service. Each RSU represents the right to receive one share of common stock.
OmniAb, Inc. (OABI) filed a Form D reporting a completed private equity offering under Rule 506(b). The filing states a total offering amount of $29,998,991, with $29,998,991 sold and
Schedule 13G/A filed for OmniAb, Inc. (OABI) discloses that several related entities and individuals report beneficial ownership of the issuer's common stock. Ash X LP and RLG GP each report ownership of 8,271,347 shares, representing approximately 5.8% of the outstanding common stock. RLG Capco II LLC holds 1,800,246 shares (about 1.3%) and Joel Greenblatt holds 1,428,571 shares (about 1.0%). Robert Goldstein is reported as beneficial owner of 10,071,593 shares (about 7.0%), reflecting combined holdings through entities he controls. The percentages are calculated using 122,701,294 shares outstanding as of July 30, 2025 plus 21,254,106 additional shares issued on August 25, 2025. The filing states the holdings are not intended to influence control of the issuer.